ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA.', Journal of Clinical Oncology, 41, pp. 318 - 318, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.318
,2023, 'PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.', Journal of Clinical Oncology, 41, pp. TPS397 - TPS397, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps397
,2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398
,2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677
,2023, 'Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium–Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes', International Journal of Radiation Oncology Biology Physics, 115, pp. 106 - 117, http://dx.doi.org/10.1016/j.ijrobp.2022.05.044
,2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392
,2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104
,2023, 'Using PSMA imaging for prognostication in localized and advanced prostate cancer', Nature Reviews Urology, 20, pp. 23 - 47, http://dx.doi.org/10.1038/s41585-022-00670-6
,2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773
,2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086
,2023, 'OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer', Radiotherapy and Oncology, 182, pp. S335 - S336, http://dx.doi.org/10.1016/s0167-8140(23)08607-3
,2023, 'The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer', European Urology Open Science, 57, pp. S45 - S45, http://dx.doi.org/10.1016/s2666-1683(23)01325-3
,2022, '18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging', European Urology, 82, pp. 510 - 511, http://dx.doi.org/10.1016/j.eururo.2022.06.001
,2022, 'Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups', BJU International, 130, pp. 32 - 39, http://dx.doi.org/10.1111/bju.15762
,2022, 'High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer', BJU International, 130, pp. 5 - 7, http://dx.doi.org/10.1111/bju.15736
,2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2
,2022, 'The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63, pp. 1644 - 1650, http://dx.doi.org/10.2967/jnumed.121.263448
,2022, 'EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy', European urology oncology, 5, pp. 530 - 536, http://dx.doi.org/10.1016/j.euo.2022.05.003
,2022, 'Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?', European Urology Open Science, 44, pp. 11 - 12, http://dx.doi.org/10.1016/j.euros.2022.07.015
,2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342
,2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772
,2022, 'Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 49, pp. 3289 - 3294, http://dx.doi.org/10.1007/s00259-022-05756-2
,2022, 'All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others', European urology oncology, 5, pp. 283 - 284, http://dx.doi.org/10.1016/j.euo.2022.04.002
,2022, 'The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective', Journal of Nuclear Medicine, 63, pp. 819 - 822, http://dx.doi.org/10.2967/JNUMED.122.263996
,2022, 'The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma', Annals of Surgical Oncology, 29, pp. 2871 - 2881, http://dx.doi.org/10.1245/s10434-021-11231-3
,2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552
,2022, 'EDITORIAL COMMENT', Journal of Urology, 207, pp. 348 - 349, http://dx.doi.org/10.1097/JU.0000000000002254.01
,2022, 'Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI', Clinical and Translational Radiation Oncology, 32, pp. 41 - 47, http://dx.doi.org/10.1016/j.ctro.2021.11.006
,2022, 'FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 33, pp. 99 - 106, http://dx.doi.org/10.1016/j.annonc.2021.10.003
,2022, 'Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study', Journal of Nuclear Medicine, 63, pp. 1531 - 1536, http://dx.doi.org/10.2967/jnumed.121.263139
,2022, 'Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer', Journal of Nuclear Medicine, 63, pp. 1659 - 1664, http://dx.doi.org/10.2967/JNUMED.121.263743
,2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002
,2021, 'The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study[Formula presented]', European Urology, 80, pp. 682 - 689, http://dx.doi.org/10.1016/j.eururo.2021.08.002
,2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491
,2021, 'Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer', Internal Medicine Journal, 51, pp. 1722 - 1726, http://dx.doi.org/10.1111/imj.15515
,2021, 'UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342, http://dx.doi.org/10.1111/bju.15384
,2021, 'Targeted radioactive therapy for prostate cancer – Authors' reply', The Lancet, 398, pp. 488, http://dx.doi.org/10.1016/S0140-6736(21)01060-6
,2021, 'External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study', European Urology, 80, pp. 234 - 242, http://dx.doi.org/10.1016/j.eururo.2021.05.006
,2021, 'Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma', Annals of Surgical Oncology, 28, pp. 4561 - 4569, http://dx.doi.org/10.1245/s10434-020-09270-3
,2021, 'Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT', Clinical and Translational Imaging, 9, pp. 215 - 220, http://dx.doi.org/10.1007/s40336-021-00421-4
,2021, 'External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?', European Urology Open Science, 28, pp. 47 - 51, http://dx.doi.org/10.1016/j.euros.2021.04.002
,2021, 'Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer', Future Oncology, 17, pp. 2225 - 2241, http://dx.doi.org/10.2217/fon-2020-1293
,2021, 'Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).', Journal of Clinical Oncology, 39, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9508
,2021, 'E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 1626 - 1638, http://dx.doi.org/10.1007/s00259-021-05245-y
,2021, '[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', The Lancet, 397, pp. 797 - 804, http://dx.doi.org/10.1016/S0140-6736(21)00237-3
,2021, '68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 477 - 482, http://dx.doi.org/10.1007/s00259-020-04944-2
,2021, 'Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 655 - 656, http://dx.doi.org/10.1007/s00259-020-04983-9
,2021, 'False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 501 - 508, http://dx.doi.org/10.1007/s00259-020-04945-1
,2021, 'Pilot Trial Comparing the Performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/ CT in the Detection of Prostate Cancer Recurrence in Men with Rising PSA Following Radical Prostatectomy', Journal of Radiology and Medical Imaging, https://meddocsonline.org/journal-of-radiology-and-medical-imaging/pilot-trial-comparing-the-performance-of-68Ga-PSMA-11-PET-CT-to-18F-PSMA-1007-PET-CT-in-the-detection-of-prostate-cancer-recurrence-in-men-with-rising-PSA-following-radical-prostatectomy.pdf
,2021, 'Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review', Advances in Urology, 2021, http://dx.doi.org/10.1155/2021/1544208
,